In adults with multiple sclerosis, how does alemtuzumab compare with other drug therapies?doi:10.1002/CCA.1480S. TortJohn Wiley & Sons, Ltd
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30:99–105. 54. Uchimura I, Shiraki H. A contribution to the classification and the pathogenesis of demyelinating encephalomyelitis. J Neuropathol Exp Neurol. 1957;16:139–203. 55...
Experimentation is ongoing to see if new combinations may work better than established treatments. For example, aNew England Journal of Medicinestudyof more than 500 CLL patients found that combination therapy of ibrutinib and rituximab may be more effective than FCR (aprogression-free survival rateof...
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30:99–105. 54. Uchimura I, Shiraki H. A contribution to the classification and the pathogenesis of demyelinating encephalomyelitis. J Neuropathol Exp Neurol. 1957;16:139–203. 55...
40 Alemtuzumab may also have some activity in leukemic ATL: a phase 2 study of demonstrated responses in 12 of 15 patients with acute ATL and 2 of 3 patients with chronic ATL whereas responses were seen in only 1 of 11 patients with lymphoma but the duration of response was short (median...
Prior IFD: 199 Candida spp., 281 IA, 50 others (including 9 Mucorales and 19 other IMD), and 295 suspected; retrospective 825 24% vs 17% at 1 y (prior IFD vs controls) NS RFs for IFD relapse: prior IFD, older age, receipt of alemtuzumab, advanced malignancy, ATG exposure, cord blo...
In particular, fingolimod, natalizumab, and alemtuzumab were associated with the lowest risk of progression to SPMS, and treatment was especially beneficial when started sooner — less than five years after disease onset — rather than later. Tremlett also coauthored a systematic review of MS resear...
The use of serotherapy in conditioning regimens can include agents such as antithymocyte globulin (ATG) or alemtuzumab (anti-CD52+). Serotherapy is used to deplete the recipient's T cells in vivo, preventing rejection of the graft, as well as to reduce the risk of aGVHD. However, ATG ha...
The clearest example of this is the addition of the anti-CD52 antibody, alemtuzumab, to CHOP, which in several phase 2 studies demonstrated impressive CR rates of 65% to 71%; however, serious treatment-related complications were observed including John Cunningham virus encephalitis, invasive ...
Alemtuzumab: 30 mg × 3/wk for 4-12 wk Third or > 100 Small series of relapsed/refractory wAIHAs and progressive CLL (8 patients) 39, 40 Cyclosporine: 3-5 mg/kg per day Third or > 56 Small series of relapsed/refractory wAIHAs (16 patients) 41 Splenectomy Third or > 69-78 Old re...